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Objective. The aim of this study was to determine whether pregnancy increases the recurrence risk of cutaneous malignant
melanoma (CMM) in women with a history of stage I CMM. Methods. The electronic medical databases of Medline and Embase
were explored. All 1084 obtained articles were screened on title and abstract using predetermined inclusion and exclusion criteria.
A critical appraisal of relevance and validity was conducted on the remaining full text available articles. Results. Two studies were
selected. Both studies revealed no significant diﬀerence in disease-free survival between women with stage I CMM and the control
population. Conclusion. Pregnancy does not increase the recurrence risk of CMM in women with a history of stage I CMM.
1. Clinical Scenario
A 33-year-old nulliparous woman was seen by the derma-
tologist because of a mole on her leg, which had been
growing and itching over the past year. After excision of
the lesion and pathological examination, the diagnosis made
was a cutaneous malignant melanoma, with Clark level IV,
a Breslow thickness of 1.25 cm-and tumor-free margins.
Because excision had been successful, only a sentinel lymph
node dissection was conducted which yielded no metastatic
spread. The conclusive diagnosis therefore was a stage I
cutaneous malignant melanoma. Every three months now,
the patient is seen by the dermatologist in order to keep a
close watch on the development of recurrence. Currently, she
and her partner would like to embark on a first pregnancy.
2. Introduction
The incidence of Cutaneous Malignant Melanoma (CMM)
has shown a rapid increase over the past decades, therefore
substantiating a growing problem. About 27% of the non-
invasive CMM diagnosed in the Netherlands in 2003 were
seen in women between 30 and 44 years of age, of which
13% eventually died because of the disease. The currently
known factors determining outcome are mostly the skin
location of the melanoma, the Breslow thickness, and the
Clark level [1, 2]. Keeping in view the possibility of tumor
sensitivity to hormones, although the possible mechanism of
this influence is still unknown, the question arises whether
pregnancy influences the recurrence of CMM [2]. In the
past, some studies have suggested a negative influence [3, 4],
whereas other studies showed no eﬀect of pregnancy on
the prognosis of cutaneous malignant melanoma [5, 6].
Therefore, the aim of this article is to answer the following
clinical question:
does [pregnancy] increase the [recurrence) risk (of
cutaneous malignant melanoma] in [women with a history
of stage I cutaneous malignant melanoma]?
Pregnancy was defined as occurring within five years of
CMM diagnosis in previously nulliparous women. Stage I
cutaneous melanoma was defined as a malignant melanoma
localized to the site of origin on the skin, with no evidence
of regional or distant spread [7]. Recurrence was defined as a
subsequent manifestation of CMM within ten years of initial
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Figure 1: Flow chart.
diagnosis and treatment. In addition, the disease-free sur-
vival is a period of time in which no CMM recurrence is seen.
3. Methods
3.1. Search and Selection. Synonyms for domain, deter-
minant and outcome were identified using Thesaurus,
Embase EMTREE-tool, Medline MesH-terms, and Index
[Title/Abstract] and were applied in the electronic databases
of Embase andMedline. This full cover search resulted in 491
articles in Medline and 593 articles in Embase (Table 1). The
title and abstract of a total of 1084 articles were subsequently
screened for their relevance concerning the clinical question,
based on the following inclusion criteria: pregnancy within
five years of CMM diagnosis in previously nulliparous
women, the primary diagnosis being stage I cutaneous
malignant melanoma, and CMM recurrence within ten
years of the primary diagnosis. The exclusion criteria are
shown in the flow chart (Figure 1). All decisions were made
through a consensus of all three authors. Upon screening, 12
articles remained for further analysis. A total of seven articles
appeared to be full text available.
Table 1: Search strategy.
Database Searcha Hits
Medline
((Woman OR Women OR Female OR
Females OR Patient OR Patients) AND
(Skin OR Cutaneous OR Malignant OR
Melanoma OR Melanomas)) AND
(Pregnancy OR Pregnancies OR Pregnant
OR Gravidity OR Gravidities OR
Gestation) AND (Recurrent OR
Recurrence OR Recurrences OR
Recurring OR Recidive OR Recidives OR
Recidivism OR Recidivisms OR
Recidivating OR Recidivation OR
Relapsing OR Relapse OR Relapses)
491
Embase Idem Medline 593
aThe original search was performed on 04-01-2008 according to the
strategy above.
An update performed on 01-05-2010 following the same search strategy
yielded no additional relevant articles.
3.2. Critical Appraisal. The selected articles were screened
for relevance of domain, determinant, and outcome. As a
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Table 3: Influence of pregnancy on recurrence of cutaneous malignant melanoma in women.
Study Population (n)
Eﬀect Precision
χ2(∗) RR P-value 95% CI
Reintgen et al. [9] 43 patients 0.04 univariate — .80 univariate —
585 controls 0.0 multivariate — 1.00 multivariate —
MacKie et al. [10] 85 patients — 1.21 (
∗∗) .66 0.52–2.79
143 controls — 0.71 (∗∗) .54 0.23–2.15
(∗)With χ2, the chi-square test is pronounced, which was used to test the significance of diﬀerences between the patient and the control groups. A concomitant
P-value > .05 means that a correlation between pregnancy and CMM recurrence is not likely, and that if there is a correlation at all, this is not very strong,
as suggested by the small χ2 -values of 0.04 and 0.0 in the univariate and multivariate analyses, respectively.
(∗∗) Compared to women diagnosed with a CMM in between pregnancies.
result, four articles remained for validity screening. These
articles were evaluated on the basis of the components
shown in Table 2. Because Shaw [5] and Bork et al. [6]
failed to report any eﬀect or precision measures and did not
compare patients with controls, these studies were excluded
from further assessment. In contrast, Reintgen et al. [9] and
MacKie et al. [10] didmeet the criteria for a valid study with a
level of evidence (Oﬀringa et al. [8]) of 2B and were therefore
considered valuable for answering the clinical question.
4. Results
Reintgen et al. [9] set up a retrospective case control study,
whose objective was to assess whether pregnancy within
five years of diagnosis would influence the ten-year disease-
free interval in women with stage I cutaneous malignant
melanoma. Patients were matched with a control population
consisting of female stage I CMM patients between the age of
15 and 44 years, who were not pregnant either at diagnosis
or within five-years of diagnosis. The study showed that the
ten-yeardisease-free interval of the patient group did not
significantly diﬀer from that of the control group (Table 3).
MacKie et al. [10] also established a retrospective case
control study, in which the eﬀect of pregnancy on the
twenty year-disease-free survival after diagnosis of stage I
cutaneous malignant melanoma was investigated. Patients
were matched with a control population of women who
had completed all pregnancies before a stage I CMM
was diagnosed. The study yielded a relative risk of 1.21,
which would suggest a slight eﬀect of pregnancy on CMM
recurrence. After regression analysis however, this did not
prove to be significant (Table 3).
5. Conclusion
According to both Reintgen et al. [9] and MacKie et al. [10],
pregnancy does not increase the recurrence risk of cutaneous
malignant melanoma in women with a history of stage I
cutaneous malignant melanoma.
6. Discussion
This evidence-based case report suggests that there is no
negative influence of pregnancy on the recurrence of cuta-
neous malignant melanoma in women. There are however a
number of drawbacks with respect to the critically appraised
studies. Firstly, both Reintgen et al. [9] and MacKie et al.
[10] used only a small number of patients compared to the
relatively large control groups that were included. Secondly,
in the study of MacKie et al. [10] the results of the patient
group were not compared with the results of the control
group, but both groups were compared with women diag-
nosed with a CMM in between pregnancies. Reintgen et al.
[9] on the other hand used a more realistic control group
composed of nulliparous women with a CMM diagnosis.
Worth mentioning is the use of a regression analysis in both
the study of Reintgen et al. [9] and that of MacKie et al. [10],
which is a reliable statistical analysis method to determine
the eﬀect of possible confounders.
7. Recommendation
The best available evidence does not show any eﬀect of
pregnancy on the recurrence risk of cutaneous malignant
melanoma in women. Nevertheless, a careful recommenda-
tion should be given, with Breslow thickness, Clark level,
and skin localization taken into account. Because recurrence,
independent of pregnancy, is most likely to develop within
two to three years after CMM diagnosis and treatment
[11, 12], and since both diagnostic and therapeutical
interventions are possibly harmful to the unborn child,
appropriate timing is necessary. Women should therefore
consider delaying pregnancy for at least two to three years,
taking into account the concomitant risk of maternal age
related problems such as infertility and fetal developmental
abnormalities.
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